Properdin

A 53-kDa protein that is a positive regulator of the alternate pathway of complement activation (COMPLEMENT ACTIVATION PATHWAY, ALTERNATIVE). It stabilizes the ALTERNATIVE PATHWAY C3 CONVERTASE (C3bBb) and protects it from rapid inactivation, thus facilitating the cascade of COMPLEMENT ACTIVATION and the formation of MEMBRANE ATTACK COMPLEX. Individuals with mutation in the PFC gene exhibit properdin deficiency and have a high susceptibility to infections.

Also Known As:

Networked: 476 relevant articles (7 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stover, Cordula M: 13 articles (01/2021 - 03/2008)
2.	Song, Wen-Chao: 12 articles (01/2018 - 01/2008)
3.	Stover, Cordula: 10 articles (01/2019 - 04/2010)
4.	Miwa, Takashi: 9 articles (01/2018 - 01/2008)
5.	Schwaeble, Wilhelm J: 8 articles (12/2018 - 03/2008)
6.	Ferreira, Viviana P: 7 articles (01/2020 - 07/2010)
7.	Gullipalli, Damodar: 7 articles (01/2018 - 01/2013)
8.	Cortes, Claudio: 6 articles (01/2020 - 07/2010)
9.	Sato, Sayaka: 6 articles (01/2018 - 01/2013)
10.	Daha, Mohamed R: 4 articles (01/2021 - 04/2010)

Related Diseases

1.	Infections 04/08/2014 - "Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection." 12/01/2008 - "This study concluded that patients with low expression of properdin should be advised to take extensive preventive measures and seek early management with appropriate treatments against infection." 05/01/1958 - "Experimental studies of the in vivo relationships of the properdin system to resistance to infection." 01/01/2021 - "Thus, depending on the subtype, properdin can either limit or aggravate IAV infection in the host." 01/01/2021 - "Collectively, we conclude that infiltrating neutrophils at the site of IAV infection can release properdin, which then acts as an entry inhibitor for pandemic H1N1 subtype while suppressing viral replication and inducing an anti-inflammatory response. "
2.	Reperfusion Injury 01/01/2023 - "Properdin inhibition ameliorates hepatic ischemia/reperfusion injury without interfering with liver regeneration in mice." 01/01/2023 - "Corrigendum: HBSP improves kidney ischemia-reperfusion injury and promotes repair in properdin deficient mice via enhancing phagocytosis of tubular epithelial cells." 01/01/2023 - "HBSP improves kidney ischemia-reperfusion injury and promotes repair in properdin deficient mice via enhancing phagocytosis of tubular epithelial cells." 01/01/2017 - "Role of Complement Properdin in Renal Ischemia-Reperfusion Injury." 10/01/2014 - "Renal ischemia-reperfusion injury in the Crry conditional knockout mice was prevented by blocking C3 and C5 activation using an anti-properdin or anti-C5 monoclonal antibody (mAb), respectively. "
3.	Arthritis (Polyarthritis) 10/01/2010 - "Ab neutralization of properdin in WT mice similarly ameliorated arthritis development, whereas reconstitution of properdin-null mice with exogenous properdin restored arthritis sensitivity. " 07/25/2012 - "Abrogated RANKL expression in properdin-deficient mice is associated with better outcome from collagen-antibody-induced arthritis." 07/25/2012 - "Our data show that the active involvement of properdin in arthritis is related to an increased proinflammatory cytokine production and RANKL expression on immune cells and to a stimulation of the RANKL-dependent osteoclast differentiation." 10/01/2010 - "Properdin deficiency rescued mice from AP complement–mediated embryonic lethality caused by deficiency of the membrane complement regulator Crry and markedly reduced disease severity in the K/BxN model of arthritis. " 04/01/2010 - "Using properdin-deficient and wild-type mice, we have investigated the role of properdin in development and progression of zymosan-induced arthritis. "
4.	Kidney Diseases (Kidney Disease) 01/01/2013 - "Mutations in fH associate with several human kidney diseases, but whether inhibiting properdin would be beneficial in these diseases is unknown. " 05/01/1972 - "Role of properdin in kidney diseases." 01/01/2019 - "Role of properdin in complement-mediated kidney diseases."
5.	Convalescence 12/01/1977 - "Serum properdin titers were decreased in 14 patients at the time of admission, in 12 patients 2 hours after treatment, and in none during convalescence. " 10/01/1977 - "During convalescence, complement levels were normal or elevated in most of the patients, but mean levels of properdin remained significantly below normal in bacteremic patients. " 09/01/1991 - "A decrease in the levels of complement and properdin during convalescence is seemingly linked with their consumption for the formation of immune complexes, eliminated from the body."

Related Drugs and Biologics

1.	Complement System Proteins (Complement)
2.	Antigen-Antibody Complex (Immune Complex)
3.	Lipopolysaccharides
4.	CD55 Antigens (Decay Accelerating Factor)
5.	Anaphylatoxins
6.	Endotoxins
7.	Collagen
8.	Complement Factor B (Factor B)
9.	Immunoglobulin G (IgG)
10.	Immunoglobulin A (IgA)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration
3.	Radiotherapy
4.	Drug Therapy (Chemotherapy)
5.	Aftercare (After-Treatment)